MeSH Review:
Osteomalacia
John,
Wickert,
Zaar,
Jonsson,
Grauer,
Ruppersberger,
Schmidt-Gayk,
Murer,
Ziegler,
Blind,
Dupond,
Mahammedi,
Prié,
Collin,
Gil,
Blagosklonov,
Ricbourg,
Meaux-Ruault,
Kantelip,
Pascussi,
Robert,
Nguyen,
Walrant-Debray,
Garabedian,
Martin,
Pineau,
Saric,
Navarro,
Maurel,
Vilarem,
Carpenter,
Moltz,
Ellis,
Andreoli,
McCarthy,
Centrella,
Bryan,
Gundberg,
- Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. Brooks, M.H., Bell, N.H., Love, L., Stern, P.H., Orfei, E., Queener, S.F., Hamstra, A.J., DeLuca, H.F. N. Engl. J. Med. (1978)
- Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. Harrell, R.M., Lyles, K.W., Harrelson, J.M., Friedman, N.E., Drezner, M.K. J. Clin. Invest. (1985)
- Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. Reed, J.S., Meredith, S.C., Nemchausky, B.A., Rosenberg, I.H., Boyer, J.L. Gastroenterology (1980)
- Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Hodsman, A.B., Sherrard, D.J., Wong, E.G., Brickman, A.S., Lee, D.B., Alfrey, A.C., Singer, F.R., Norman, A.W., Coburn, J.W. Ann. Intern. Med. (1981)
- Neuromuscular disease in secondary hyperparathyroidism. Mallette, L.E., Patten, B.M., Engel, W.K. Ann. Intern. Med. (1975)
- Dietary intakes and nutritional status of old people with dementia living at home in Oslo. Nes, M., Sem, S.W., Rousseau, B., Bjørneboe, G.E., Engedal, K., Trygg, K., Pedersen, J.I. European journal of clinical nutrition. (1988)
- Octreotide therapy for tumor-induced osteomalacia. Seufert, J., Ebert, K., Müller, J., Eulert, J., Hendrich, C., Werner, E., Schuüze, N., Schulz, G., Kenn, W., Richtmann, H., Palitzsch, K.D., Jakob, F. N. Engl. J. Med. (2001)
- Letter: Anticonvulsants, acetazolamide and osteomalacia. Mallette, L.E. N. Engl. J. Med. (1975)
- Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. Pascussi, J.M., Robert, A., Nguyen, M., Walrant-Debray, O., Garabedian, M., Martin, P., Pineau, T., Saric, J., Navarro, F., Maurel, P., Vilarem, M.J. J. Clin. Invest. (2005)
- Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. Berndt, T., Craig, T.A., Bowe, A.E., Vassiliadis, J., Reczek, D., Finnegan, R., Jan De Beur, S.M., Schiavi, S.C., Kumar, R. J. Clin. Invest. (2003)
- FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. Riminucci, M., Collins, M.T., Fedarko, N.S., Cherman, N., Corsi, A., White, K.E., Waguespack, S., Gupta, A., Hannon, T., Econs, M.J., Bianco, P., Gehron Robey, P. J. Clin. Invest. (2003)
- Abnormal sulfate metabolism in vitamin D-deficient rats. Fernandes, I., Hampson, G., Cahours, X., Morin, P., Coureau, C., Couette, S., Prie, D., Biber, J., Murer, H., Friedlander, G., Silve, C. J. Clin. Invest. (1997)
- Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia. Wills, M.R., Savory, J. Lancet (1983)
- Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy. Pierides, A.M., Ellis, H.A., Simpson, W., Dewar, J.H., Ward, M.K., Kerr, D.N. Lancet (1976)
- Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol. Papapoulos, S.E., Clemens, T.L., Fraher, L.J., Gleed, J., O'Riordan, J.L. Lancet (1980)
- Vitamin D deficiency and bone disease in patients with Crohn's disease. Driscoll, R.H., Meredith, S.C., Sitrin, M., Rosenberg, I.H. Gastroenterology (1982)
- Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Compston, J.E., Thompson, R.P. Lancet (1977)
- Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Xu, Y., Hashizume, T., Shuhart, M.C., Davis, C.L., Nelson, W.L., Sakaki, T., Kalhorn, T.F., Watkins, P.B., Schuetz, E.G., Thummel, K.E. Mol. Pharmacol. (2006)
- Somatic mutations of the MEN1 gene and microsatellite instability in a case of tertiary hyperparathyroidism occurring during high phosphate therapy for acquired, hypophosphatemic osteomalacia. Sato, K., Obara, T., Yamazaki, K., Kanbe, M., Nakajima, K., Yamada, A., Yanagisawa, T., Kato, Y., Nishikawa, T., Takano, K. J. Clin. Endocrinol. Metab. (2001)
- Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H.S., Jüppner, H., Jonsson, K.B. Endocrinology (2004)
- Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. D'Haese, P.C., Couttenye, M.M., Lamberts, L.V., Elseviers, M.M., Goodman, W.G., Schrooten, I., Cabrera, W.E., De Broe, M.E. Clin. Chem. (1999)
- Theoretical physical chemical studies of the cause of fluoride-induced osteomalacia. Wiers, B.H., Francis, M.D., Hovancik, K., Ritchie, C.K., Baylink, D.J. J. Bone Miner. Res. (1990)
- Aluminium-related osteomalacia: response to reverse osmosis water treatment. Smith, G.D., Winney, R.J., McLean, A., Robson, J.S. Kidney Int. (1987)
- Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Argiro, L., Desbarats, M., Glorieux, F.H., Ecarot, B. Genomics (2001)
- The effects of anticonvulsant drugs on vitamin D3-activating cytochrome P-450-linked monooxygenase systems. Tomita, S., Ohnishi, J., Nakano, M., Ichikawa, Y. J. Steroid Biochem. Mol. Biol. (1991)
- Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. Nampei, A., Hashimoto, J., Hayashida, K., Tsuboi, H., Shi, K., Tsuji, I., Miyashita, H., Yamada, T., Matsukawa, N., Matsumoto, M., Morimoto, S., Ogihara, T., Ochi, T., Yoshikawa, H. J. Bone Miner. Metab. (2004)
- A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma. John, M.R., Wickert, H., Zaar, K., Jonsson, K.B., Grauer, A., Ruppersberger, P., Schmidt-Gayk, H., Murer, H., Ziegler, R., Blind, E. Bone (2001)
- Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. Yamashita, T., Konishi, M., Miyake, A., Inui, K., Itoh, N. J. Biol. Chem. (2002)
- Osteocalcin production in primary osteoblast cultures derived from normal and Hyp mice. Carpenter, T.O., Moltz, K.C., Ellis, B., Andreoli, M., McCarthy, T.L., Centrella, M., Bryan, D., Gundberg, C.M. Endocrinology (1998)
- Fracture osteomalacia, CAPD, and aluminium. Kingswood, C., Banks, R.A., Bunker, T., Harrison, P., Mackenzie, C. Lancet (1983)
- Histochemical demonstration of iron but not aluminum in a case of dialysis-associated osteomalacia. Phelps, K.R., Vigorita, V.J., Bansal, M., Einhorn, T.A. Am. J. Med. (1988)
- Results of subtotal parathyroidectomy in hemodialysis patients. Johnson, W.J., McCarthy, J.T., van Heerden, J.A., Sterioff, S., Grant, C.S., Kao, P.C. Am. J. Med. (1988)
- Dissociation between the effects of endogenous parathyroid hormone on adenosine 3',5'-monophosphate generation and phosphate reabsorption in hypocalcemia due to vitamin D depletion: an acquired disorder resembling pseudohypoparathyroidism type II. Rao, D.S., Parfitt, A.M., Kleerekoper, M., Pumo, B.S., Frame, B. J. Clin. Endocrinol. Metab. (1985)
- Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Dupond, J.L., Mahammedi, H., Prié, D., Collin, F., Gil, H., Blagosklonov, O., Ricbourg, B., Meaux-Ruault, N., Kantelip, B. Bone (2005)